B Symptoms

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 141135 Experts worldwide ranked by ideXlab platform

And Ahmed Bedewy - One of the best experts on this subject based on the ideXlab platform.

  • CD163 and c-Met expression and serum free light chain in advanced classical Hodgkin’s lymphoma ( correlation with different clinicopathological parameters)
    The Egyptian Journal of Haematology, 2013
    Co-Authors: And Ahmed Bedewy, Shereen M. El-maghraby, Magdy M. L. Bedewy
    Abstract:

    Background Advances in the understanding of classical Hodgkin’s lymphoma (cHL) Biology and immunology show that infiltrating immune cells and cytokines play different roles in relation to clinical outcomes. High levels of expression of the monocyte/macrophage lineage antigen CD163 were suggested to exert protumor effects. Lymphoid malignancies were found to express c-Met with a possiBle role in the pathogenesis of these diseases. Lymphoid malignancies often have a polyclonal B-cell infiltrate that can secrete immunogloBulins. This study aimed to evaluate the expressions of CD163 and c-Met and serum free light chain (sFLC) in relation to the clinicopathological features in patients with advanced cHL. Materials and methods Thirty-four patients with cHL were enrolled. CD163 and c-Met expressions were assessed immunohistochemically on lymph node Biopsy sections together with a pretreatment estimation of sFLC using Enzyme Linked ImmunosorBent Assay (ELISA). Results The median age of the patients was 30 years, with a 1 : 1 male to female ratio. High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score of at least 3, mixed cellularity suBtype, and low response to treatment. Also, high c-Met expression was correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower complete remission rates. Elevated sFLC correlated with increased age at diagnosis, lymphopenia, International Prognostic Score of at least 3, B Symptoms, and lower complete remission rates. Conclusion In cHL, high expression of CD163 and c-Met and elevated sFLC correlates with adverse outcome.

  • CD163 and c-Met expression in the lymph node and the correlations Between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
    Blood research, 2013
    Co-Authors: Magdy M. L. Bedewy, Shereen M. El-maghraby, And Ahmed Bedewy
    Abstract:

    Background Advances in the understanding of Hodgkin’s lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has Been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL). Methods We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node Biopsy sections and the levels of pretreatment sFLC were estimated using ELISA. Results High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score (IPS) ≥3, mixed cellularity suBtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS ≥3, B Symptoms, and lower complete remission rates. Conclusion In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.

Magdy M. L. Bedewy - One of the best experts on this subject based on the ideXlab platform.

  • CD163 and c-Met expression and serum free light chain in advanced classical Hodgkin’s lymphoma ( correlation with different clinicopathological parameters)
    The Egyptian Journal of Haematology, 2013
    Co-Authors: And Ahmed Bedewy, Shereen M. El-maghraby, Magdy M. L. Bedewy
    Abstract:

    Background Advances in the understanding of classical Hodgkin’s lymphoma (cHL) Biology and immunology show that infiltrating immune cells and cytokines play different roles in relation to clinical outcomes. High levels of expression of the monocyte/macrophage lineage antigen CD163 were suggested to exert protumor effects. Lymphoid malignancies were found to express c-Met with a possiBle role in the pathogenesis of these diseases. Lymphoid malignancies often have a polyclonal B-cell infiltrate that can secrete immunogloBulins. This study aimed to evaluate the expressions of CD163 and c-Met and serum free light chain (sFLC) in relation to the clinicopathological features in patients with advanced cHL. Materials and methods Thirty-four patients with cHL were enrolled. CD163 and c-Met expressions were assessed immunohistochemically on lymph node Biopsy sections together with a pretreatment estimation of sFLC using Enzyme Linked ImmunosorBent Assay (ELISA). Results The median age of the patients was 30 years, with a 1 : 1 male to female ratio. High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score of at least 3, mixed cellularity suBtype, and low response to treatment. Also, high c-Met expression was correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower complete remission rates. Elevated sFLC correlated with increased age at diagnosis, lymphopenia, International Prognostic Score of at least 3, B Symptoms, and lower complete remission rates. Conclusion In cHL, high expression of CD163 and c-Met and elevated sFLC correlates with adverse outcome.

  • CD163 and c-Met expression in the lymph node and the correlations Between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
    Blood research, 2013
    Co-Authors: Magdy M. L. Bedewy, Shereen M. El-maghraby, And Ahmed Bedewy
    Abstract:

    Background Advances in the understanding of Hodgkin’s lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has Been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL). Methods We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node Biopsy sections and the levels of pretreatment sFLC were estimated using ELISA. Results High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score (IPS) ≥3, mixed cellularity suBtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS ≥3, B Symptoms, and lower complete remission rates. Conclusion In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.

Shereen M. El-maghraby - One of the best experts on this subject based on the ideXlab platform.

  • CD163 and c-Met expression and serum free light chain in advanced classical Hodgkin’s lymphoma ( correlation with different clinicopathological parameters)
    The Egyptian Journal of Haematology, 2013
    Co-Authors: And Ahmed Bedewy, Shereen M. El-maghraby, Magdy M. L. Bedewy
    Abstract:

    Background Advances in the understanding of classical Hodgkin’s lymphoma (cHL) Biology and immunology show that infiltrating immune cells and cytokines play different roles in relation to clinical outcomes. High levels of expression of the monocyte/macrophage lineage antigen CD163 were suggested to exert protumor effects. Lymphoid malignancies were found to express c-Met with a possiBle role in the pathogenesis of these diseases. Lymphoid malignancies often have a polyclonal B-cell infiltrate that can secrete immunogloBulins. This study aimed to evaluate the expressions of CD163 and c-Met and serum free light chain (sFLC) in relation to the clinicopathological features in patients with advanced cHL. Materials and methods Thirty-four patients with cHL were enrolled. CD163 and c-Met expressions were assessed immunohistochemically on lymph node Biopsy sections together with a pretreatment estimation of sFLC using Enzyme Linked ImmunosorBent Assay (ELISA). Results The median age of the patients was 30 years, with a 1 : 1 male to female ratio. High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score of at least 3, mixed cellularity suBtype, and low response to treatment. Also, high c-Met expression was correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower complete remission rates. Elevated sFLC correlated with increased age at diagnosis, lymphopenia, International Prognostic Score of at least 3, B Symptoms, and lower complete remission rates. Conclusion In cHL, high expression of CD163 and c-Met and elevated sFLC correlates with adverse outcome.

  • CD163 and c-Met expression in the lymph node and the correlations Between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
    Blood research, 2013
    Co-Authors: Magdy M. L. Bedewy, Shereen M. El-maghraby, And Ahmed Bedewy
    Abstract:

    Background Advances in the understanding of Hodgkin’s lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has Been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL). Methods We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node Biopsy sections and the levels of pretreatment sFLC were estimated using ELISA. Results High CD163 expression correlated with increased age, B Symptoms, International Prognostic Score (IPS) ≥3, mixed cellularity suBtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B Symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS ≥3, B Symptoms, and lower complete remission rates. Conclusion In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.

Paul G. Murray - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 6 expression By Hodgkin/Reed-SternBerg cells is associated with the presence of 'B' Symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.
    British journal of haematology, 2002
    Co-Authors: Gary M. Reynolds, Lucinda Billingham, Laura J. Gray, Joanne R. Flavell, Sohrab Najafipour, J Crocker, Paul N. Nelson, Lawrence S. Young, Paul G. Murray
    Abstract:

    Summary. Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a numBer of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association Between elevated serum levels of IL-6 and unfavouraBle prognosis, including advanced stage and the presence of ‘BSymptoms and with reduced survival. Although IL-6 expression has Been demonstrated in Both the malignant Hodgkin/Reed–SternBerg (HRS) cells and in the various non-malignant cells present in HD Biopsies, a relationship Between expression of IL-6 By the tumour and outcome measures has not Been estaBlished. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of Biopsy material By means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression By HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0·02) and with an increased prevalence of ‘BSymptoms (P = 0·04). IL-6 expression By HRS cells was not associated with Epstein–Barr virus status (P = 0·57). In summary, the results suggest that IL-6 expression By HRS cells may contriBute to the presence of ‘BSymptoms and to a decreased likelihood to achieve a complete remission in HD patients.

  • interleukin 6 expression By hodgkin reed sternBerg cells is associated with the presence of B Symptoms and failure to achieve complete remission in patients with advanced hodgkin s disease
    British Journal of Haematology, 2002
    Co-Authors: Gary M. Reynolds, Lucinda Billingham, Laura J. Gray, Joanne R. Flavell, Sohrab Najafipour, J Crocker, Paul N. Nelson, Lawrence S. Young, Paul G. Murray
    Abstract:

    Summary. Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a numBer of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association Between elevated serum levels of IL-6 and unfavouraBle prognosis, including advanced stage and the presence of ‘BSymptoms and with reduced survival. Although IL-6 expression has Been demonstrated in Both the malignant Hodgkin/Reed–SternBerg (HRS) cells and in the various non-malignant cells present in HD Biopsies, a relationship Between expression of IL-6 By the tumour and outcome measures has not Been estaBlished. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of Biopsy material By means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression By HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0·02) and with an increased prevalence of ‘BSymptoms (P = 0·04). IL-6 expression By HRS cells was not associated with Epstein–Barr virus status (P = 0·57). In summary, the results suggest that IL-6 expression By HRS cells may contriBute to the presence of ‘BSymptoms and to a decreased likelihood to achieve a complete remission in HD patients.

Wu Qing - One of the best experts on this subject based on the ideXlab platform.

  • Analysis of Treatment result of Tonsillar Non Hondgkin's Lymphoma
    Journal of Qilu Oncology, 2000
    Co-Authors: Wu Qing
    Abstract:

    OBjective:To evaluate treatment method, result and main cause of failure and prognostic factors of tonsillar Non Hondgkin's lymphoma. Methods:Fifty seven patients of tonsillar NHL were treated in our hospital from 1988 to 1993. The age ranged from 16 to 76,with a median age of 48. Ann ArBor was used for staging,including stage I 4 cases, stage Ⅱ 29 cases,stage Ⅲ9 cases,stage Ⅳ 5 cases. Seven patients had B Symptoms.Working Formulation was used in pathologic classification which was low grade 3 cases, intermediate grade 29 cases,high grade 20 cases and undivided 5 cases. Seven cases were treated By radiotherapy alone, 50 cases with chemotherapy and radiotherapy. When more than 2 tonsil sites were involved or with B Symptoms,or lymph nodes enlargement more than 5 cm in diameter, one cycle of chemotherapy was given Before irradiation. CHOP or COPP regimen was given for 2-6 cycles. The local extended fields which include Waldeyer's ring and total cervical lymph nodes were irradiated By 60 Co and deep X rays.Results: The life taBle method was used for 5 year survival rate. The whole 5 year survival rate was 46.5%, They were 75 0%,58 7%,0 0,0 0. respectively.CR rate was 59.7% and residual rate(PR+MR+PD) were 40.3%. The residual group had no 2 years survival. In the end of the treatment, the tumor regressive condition was closely related to the chinical stage, the type of pathological, the whole health condition Before treatment and with B Symptoms or without B Symptoms. Conclusions: It is suggested that patient with aBove stage Ⅱ,intermediary and high grade malignant should use chemotherapy followed By radiation then chemotherapy. The key of raising survival rate was the achivement of CR at the first treatment:Recurrence and diffusion were the main cause of failure. The prognosis was very poor those who Before treatment the Karnofsky scores was 60 or with B Symptoms or high grade of stage Ⅲ;the B Symptoms had not changed during the treatment or after treatment the tumor was residual.